PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PAM”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,135 records · Page 63Linked to original sources

Identification of pregnancy-associated alpha-macroglobulin on the surface of peripheral blood leucocyte populations.

Pregnancy-associated alpha-macroglobulin (PAM) was identified on the surface membranes of human peripheral blood leucocytes by immunofluorescent staining. Subjects having a high serum-level of the glycoprotein (pregnant and contraceptive steroid-treated women) were shown to possess a significantly greater proportion of PAM-positive cells than those (normal males) with a low concentration. However, no correlation was found between the serum values and the percentage of PAM-associated leucocytes. Studies employing purified leucocyte-types and the simultaneous detection of PAM and lymphocyte surface markers indicated that only subpopulations of T lymphocytes (23%) and monocytes (40%) were associated with this serum protein.

Adult↗

Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

Three Burkitt's lymphoma cell lines were studied for their response to cis-diamminedichloroplatinum(II) (cis-DDP) and L-phenylalanine mustard (L-PAM) with the objective of relating cytotoxicity to DNA cross-linking in human cells. Cytotoxicity was measured by cell proliferation and colony formation assays. DNA interstrand and DNA-protein cross-linking were measured by alkaline elution. Two of the cell lines showed quantitative agreement between cytotoxicity and DNA cross-linking assays following treatment with cis-DDP or L-PAM. The correlation with DNA-protein cross-linking was not as good as with interstrand cross-linking. With the third cell line, cytotoxicity and interstrand cross-linking were correlated in response to L-PAM but not in response to cis-DDP. When this line was treated with cis-DDP, cross-linking was low, but cytotoxicity was high. This line differed from the other two lines in that, following treatment with either cis-DDP or L-PAM, substantial cell lysis or disruption occurred 12 to 14 hr following treatment. The results are consistent with a general correlation between DNA cross-linking and cytotoxicity in human cells treated with bifunctional agents. An exceptional cell type, however, is described which appears to have a reduced tolerance to certain types of DNA damage, the reduced tolerance being expressed by early cell lysis or disruption.

Burkitt Lymphoma↗

[Effects of the intravenous infusion of althesin on intracranial pressure and related functions].

30-60 min after the i.m. administration of 0.5 mg atropine sulphate, 9 adult conscious neurosurgical patients on spontaneous ventilation were given a total of 12 i.v. infusions of Althesin at a rate of 0,25-0,60 ml/kg/h able to induce stable clinical and EEG levels of anaesthesia. PICm, PAm and PVCm respectively decreased in all, in ten and in six administrations. The PAm decreased below 60 mmHg in only one case, in another there was no change and in another still it increased in a stable manner. In all cases PICm, PAm and PVCm decreased by a mean of 3.88 +/- 1.22 (P < 0,05), 20,76 +/- 17,44 (P < 0,05) and 0,90 +/- 1,50 mmHg. The paCO2 generally increased and, in only one case, did it induce an intracranial hypertensive reaction; the paO2 was frequently reduced. The interruption in the infusion was followed by the regression of all effects. This appened for the PICm and PAm without dangerous rebound effects. The clinical use of Althesin in neurosurgical patients is discussed with regards to problems of anaesthesia and intensive care.

Adult↗

[Enhancing effects of the supernatant of pulmonary alveolar macrophages stimulated by BCG on proliferation on pulmonary fibroblasts].

The supernatant of pulmonary alveolar macrophages (PAM) stimulated by 7.5-60mg/L of BCG could significantly enhance proliferation of pulmonary fibroblasts (PFB), and the supernatant contained high level of TNF. This result indicated BCG could stimulate PAM to produce TNF in vitro. On the other hand, the supernatant of PAM stimulated by 50mg/L of SiO2 could also enhance proliferation of PFB, but the level of TNF in the supernatant was very low and it demonstrated the ingredient in the supernatant enhancing proliferation was not TNF. TNF showed synergistic effect with this ingredient for enhancing proliferation of PFB. Therefore, TNF produced by tuberculosis bacteria-stimulated PAM might be an important factor enhancing the development of fibrosis of silicotuberculosis.

Animals↗

Pancreastatin-like immunoreactivity in the pancreas of newborn rats.

Pancreastatin (PST), a novel COOH-terminally alpha-amidated peptide is a part of Chromogranin A molecule. Precursor processing implies also the final amidation step dependent on peptidylglycine alpha-amidating monooxygenase (PAM). High activity of PAM as well as Thyroliberin (TRH, another alpha-amidated peptide) concentration and biosynthesis were reported to be very high in neonatal rat pancreas. We followed the concentration of PST-like immunoreactivity in rat pancreas during ontogenesis. High perinatal PST concentration, resembling that of previously reported for PAM activity and TRH concentration was found. These findings suggest that perinatal PAM activation may affect a broader spectrum of pancreatic peptides.

Aging↗

Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.

We have previously shown that depletion of TCR-V beta 8+ T cells by treatment with mAb reduces the curative effectiveness of low dose melphalan (L-phenylalanine mustard; L-PAM) for mice bearing a large MOPC-315 tumor and extensive metastases. Here we show that V beta 8+/CD8+ T cell lines derived from mice that are in the process of immune-mediated eradication of a large MOPC-315 tumor as a consequence of low dose L-PAM therapy (L-PAM TuB mice) are capable of mediating tumor eradication in vivo upon adoptive transfer. Analysis of the possible mechanisms through which these cell lines bring about tumor eradication revealed that the V beta 8+/CD8+ cells can exert in vitro a potent lytic activity and secrete large amounts of IFN-gamma. Both of these activities can be triggered by the MOPC-315 but not the MOPC-104E plasmacytoma and are restricted by the MHC class I H-2Kd molecule. In vivo neutralization of IFN-gamma by treatment with mAb was found to cause a noticeable delay in tumor rejection in mice subjected to adoptive chemoimmunotherapy with low dose L-PAM and V beta 8+/CD8+ cells; however, all tumors did regress after initial growth. Thus, the V beta 8+/CD8+ cells use an IFN-gamma-dependent mechanism for the realization of their in vivo tumor-eradicating immunity. However, an IFN-gamma-independent mechanism, most likely involving direct V beta 8+/CD8+ CTL activity, is apparently also used.

Animals↗

The frequency of "do-not-resuscitate" order in aged in-patients: effect of patient- and non-patient-related factors.

OBJECTIVE: The purpose of this study was to examine the effect of patient- and non-patient-related factors (co-morbidity, demographics, and method of surveillance) on the frequency of "do-not-resuscitate" (DNR) orders in aged inpatients. METHODS: On a geriatric ward, during three different periods within 1 year, we used two different methods of data collection (with or without a form) and two different time-frames (prevalence or incidence) in studying the frequency of DNR orders, demographic data and the Pre-Arrest Morbidity (PAM) Index. RESULTS: In a sample of 261 patients the DNR decision was related to patient-related factors, including the PAM score and age. Only 3 patients with a score above 4 had no DNR order and in the group of 142 patients > 83 years 85 (59.9%) had a DNR order, compared to 52 (43.7%) of the 119 patients of 83 years or less (p < 0.05). In contrast, gender and marital status were not related to the presence of a DNR order. The variables PAM score, age, form and time-frame classified 76.6% of the cardiopulmonary resuscitation (CPR) decisions correctly and 71.5% of the DNR decisions correctly. Without attention to the resuscitation decision, the written DNR order frequency decreased significantly from 64-59% to 23%. An explanation for this variance may be the passive process of data collection, a non-patient-related factor. CONCLUSIONS: The DNR decision is related to the PAM index score and age. The variance in DNR decisions is partly related to the method of data collection, a non-patient-related factor in DNR decision-making. Without attention to the DNR/CPR decision, the DNR frequency decreased markedly.

Age Factors↗

[Changes in interleukin-1 released by pulmonary alveolar macrophage in patients with interstitial lung disease].

To evaluate the activity of PAM, levels of IL-1 released by PAM in patients with ILD (non smokers) were measured using lipopolysaccharide (LPS) stimulation and thymocyte proliferation method, healthy non-smokers as control group. The results showed that IL-1 released by PAM in patient groups both with and without LPS stimulation were significantly higher than that in control group, and also IL-1 released by PAM in healthy smokers was significantly higher than that in health non-smokers. It was indicated that IL-1 might play an important role in the process of ILD and chronic pulmonary inflammation.

Adult↗

Prediction of postoperative visual acuity in patients with total glaucomatous cupping using the Potential Acuity Meter and automated perimetry.

We evaluated the effectiveness of using the Potential Acuity Meter (PAM) and automated perimetry to predict postoperative vision in 30 advanced glaucoma patients following combined cataract extraction and trabeculectomy. Using the binomial distribution at alpha = 0.05, PAM and automated perimetry individually were significantly useful in predicting postoperative vision of 20/40 or better. Automated perimetry, but not PAM, was useful in predicting worse than 20/40 vision. Used together, automated perimetry and PAM testing were significantly useful in predicting vision worse or better than 20/40.

Aged↗

Use of endoproteases to identify catalytic domains, linker regions, and functional interactions in soluble peptidylglycine alpha-amidating monooxygenase.

The production of alpha-amidated peptides is accomplished through the sequential action of two enzymes, peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), that are contained within the bifunctional peptidylglycine alpha-amidating monooxygenase (PAM) protein. Tissue-specific alternative splicing and endoproteolysis are known to generate both soluble and integral membrane mono- and bifunctional PAM proteins. In order to investigate the functional consequences of these differences we purified PAM-3, a soluble 95-kDa bifunctional form of the enzyme, from the spent medium of stably transfected hEK-293 cells. Using NH2-terminal sequence analysis of products of limited endoproteolysis and antibody cross-reactivity we identified protease-sensitive regions at the NH2 terminus, between the 35-kDa PHM and 42-kDa PAL domains and at the COOH terminus of the protein. Endoproteolytic removal of the COOH-terminal region from the bifunctional PAM-3 protein shifted the pH optimum of PHM to a more alkaline pH, increased the turnover number (kappa(cat)) of PHM and decreased its KM for alpha-N-acetyl-Tyr-Val-Gly; the catalytic properties of PAL were not altered. Since peptide amidation can be a rate-limiting step in the biosynthesis of neuropeptides, similar increases in PHM activity in vivo may play an important role in regulating the extent of peptide alpha-amidation.

Alternative Splicing↗

Immunohistological features of basement membrane formation of uterine cervical epithelium.

The state of the basement membrane (BM) was investigated in the normal epithelium, dysplasia/carcinoma in situ (CIS) and invasive carcinoma of the uterine cervix as well as metastatic lymph nodes by performing immunohistological staining for the presence of laminin (LN) and type IV collagen (CIV) and periodic acid-methenamine silver (PAM) staining of the BM. Moreover, to clarify the relationship between the epithelial cells and the BM, simultaneous staining for proliferating cell nuclear antigen (PCNA) was performed on the repaired tissue after punch biopsy. In the normal tissues, positive linear staining was observed beneath the epithelium with both PAM staining and LN.C IV staining. Some of the cases of dysplasia/CIS were continuously positive with PAM staining. However, there were sites which showed weakening and disruption of the continuity of positive staining for LN and C IV. As a function of the histological type of invasive carcinoma, the intensity of staining for LN and C IV decreased in the order of keratinizing (K), large cell non-keratinizing (LNK) and small cell non-keratinizing (SNK) histological types. However, no correlation was found between the stage of the carcinoma and the intensity of staining. In addition, the staining of the metastatic lymph nodes was similar to that of the primary lesion, and cancer foci that were in direct contact with lymphocytes were also stained for LN and C IV. During the process of reformation of the BM, LN and C IV were already present at the time when the epithelial interstitium was still negative for PAM staining. Moreover, at the time when the epithelial basal cells were PCNA-positive, LN and C IV could not be detected, and, conversely, when PCNA was negative, LN and C IV were detected. The BM is a structure which is formed when the interstitium is in a static state, and it was surmised that the production of LN and C IV is carried out by epithelial cells, including cancerous cells. Furthermore, it was surmised that the BM is not a structure which can prevent cancer invasion and the discontinuity or intermittency of staining for LN and C IV in cancers is a result of changes in the capacity to produce the BM components due to canceration of the cells.

Basement Membrane↗

Incidence of intermediate syndrome in organophosphorous poisoning.

Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).

Adult↗

Incorporation of [U-14C]palmitate into rat brain: effect of an inhibitor of beta-oxidation.

We examined the effect of a clinically therapeutic dose of methyl 2-tetradecylglycidate (McN-3716, methyl palmoxirate, MEP) (2.5 mg/kg), an inhibitor of beta-oxidation of fatty acids, on incorporation of radiolabeled palmitic acid ([U-14C]PAM) from plasma into brain lipids of awake rats. Four hour pretreatment with 2.5 mg/kg MEP significantly increased the incorporation of [U-14C]PAM into brain lipids and substantially decreased aqueous radiolabeled metabolites in brain that can constitute unwanted background signal when analyzed by quantitative autoradiography. MEP treatment increased the lipid to aqueous background radioactivity from 0.8 to 3.0. Net rate of incorporation, k*, was significantly increased (60%) by MEP and was attributed to incorporation of [U-14C]PAM into phospholipid and triglyceride brain compartments. MEP treatment did not affect the size of the fatty acyl-CoA pool or the distribution of the various molecular acyl-CoA species. These results indicate that MEP, at a dose of 2.5 mg/kg (per os), can be used to increase incorporation of [1-(11C)]PAM for studying brain lipid metabolism in humans by positron emission tomography (PET).

Acyl Coenzyme A↗

[Pulmonary hemodynamics and long-term outcome in patients with chronic pulmonary thromboembolism and pulmonary hypertension].

We examined pulmonary hemodynamics and long-term outcome in 78 consecutive patients with chronic pulmonary thromboembolism and pulmonary hypertension. These patient's ages ranged from 19 to 75 years; the mean was 51.0 +/- 13.8 years and there was no difference in sex distribution. Mean pulmonary-artery pressure (PAm) was 44 +/- 14 mmHg and total pulmonary resistance (TPR) was 1138 +/- 634 dyne.sec.cm-5. Overall five-year survival was 58.4%, but in patients whose PAm was below 30 mmHg, the outcomes were better: all of these patients survived for at least 5 years. In patients whose PAm was above 30 mmHg, no correlation was found between the outcome and the magnitude of PAm. We divided the patients into four subgroups according to their TPR: 500 dyne.sec.cm-5 (TPR, 500 > or = TPR < 1000 dyne.sec.cm-5, 1000 < or = TPR < 1500 dyne.sec.cm-5, and 1500 dyne.sec.cm-5 < or = TPR. The five-year survivals in these groups were 100%, 88.9%, 52.4%, and 40.0%, respectively. Outcome correlated with the magnitude of TPR. TPR was useful for predicting the outcome of chronic pulmonary thromboembolism.

Adult↗

[Basic and clinical studies on pathogenesis of pulmonary Mycobacterium avium complex disease].

I have studied pathogenesis of pulmonary Mycobacterium avium complex disease (PMAC), using mouse and human alveolar macrophage (PAM) model of the infection as well as clinical evaluations. The mouse model revealed no relation between natural resistance against the bacteria and the activation of macrophages which was evaluated on the basis of releasing capacities of prostaglandin E2 and superoxide anion. The PAM model suggested that TNF-alpha and GM-CSF could activate PAM to restrict the intracellular growth of the bacteria, probably not through the superoxide anion release, but through the myeloperoxidasae-halide system. It was also found that rifamycins in combination with clarithromycin could have a good bactericidal effect in the PAM-model of the infection. Clinical evaluations suggested that defect in local pulmonary defense, such as healed pulmonary tuberculous lesions, pneumoconiosis, and COPD was more important predisposing factor than defect in systemic defense in the development of PMAC. Most patients having PMAC without predisposing factors are elderly women, the reason of which is the most important question to be answered in the future studies.

Animals↗

[The protective role of heat shock gene expression on hydrogen peroxide induced pulmonary alveolar macrophages].

The aim of this study is to determine whether heat-induced heat shock gene expression in rat pulmonary alveolar macrophages (PAMs) would protect PAMs against hydrogen peroxide (H2O2)-mediated cell killing. In response to sublethal heat shock at 42 degrees C for 2 h, the cells synthesized heat shock protein 70 kD (HSP70) and other different molecular weight heat shock proteins, which were detected with gel electrophoresis after [35S]-methionin labeling cellular protein and Western blotting analysis in PAMs. Northern blot analysis showed the induction of HSP70 mRNA with heat shock treatment. Futhermore, with heat shock, there was a significant increment of survival cells after H2O2 (1,2,3 mmol.L-1, 45 min) exposure. This increase was blocked both by Cycloheximide and by Actinomycin D, and was associated with inhibition of synthesis of HSP70 protein and transcription of HSP70 mRNA. These results strongly suggest that expression of heat shock gene (especially HSP70 gene) plays an important role in the intracelluar mechanism of cytoprotection against H2O2 in rat PAMs.

Animals↗

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.

A prospective randomized clinical trial was undertaken in 184 patients with metastatic breast carcinoma to compare single drug chemotherapy with L-phenylalanine mustard (L-PAM) and intermittent combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluourouracil (CMF). All patients had not been previously treated with cytotoxic drugs and all had objectively measurable visceral of soft tissue disease. Of the 93 patients who received CMF, 49 (53%) achieved a complete (14 patients) or partial (35 patients) regression of measurable tumor, for a median duration of 25 weeks. Eighteen of the 91 patients (20%) treated with L-PAM responded, for a median duration of 13 weeks. The toxicity was primarily hematologic, and greater in the CMF group, which also received more cycles of therapy because of the higher rate and duration of response. The overall survival of CMF-treated patients was superior to that of the single drug group. The differences were even greater when the patients were subclassified according to the presence of liver involvement or nonambulatory performance status. The superior antitumor effect of CMF over L-PAM suggests that it may be a more effective drug regimen to be used as an adjuvant to primary therapy.

Adult↗

Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols.

Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) trials evaluating three different regimens of adjuvant chemotherapy (L-PAM, L-PAM + 5-FU, L-PAM + 5-FU + MTX) in patients with primary breast cancer and positive axillary nodes indicate that each regimen has significantly contributed toward achieving the initial goal of such therapy, namely to diminish or prevent treatment failure in all or major subsets of patients during the first two years following operation when women are at greatest risk for a recurrence. Because of this hazard, chemotherapy was administered in all protocols for two years. Findings were examined at the end of the first year of therapy and at the termination of the second year for those who entered that year of therapy disease-free in order to determine whether the second year of treatment contributed a benefit beyond that achieved from the first year of therapy. A reduction in the incidence of treatment failure was evident in every subgroup of patients at completion of the first year of therapy. There was evidence of added improvement during the second year of treatment in patients aged 49 years or younger but not in those aged 50 years or older. Despite the finding, it is not possible from these studies to be absolutely certain that a second year of therapy is or is not advantageous. Findings obtained to date from the three studies indicate that patients completing two years of chemotherapy who are disease-free display a subsequent treatment failure rate that is no greater than that observed in untreated patients who survived two years without recurrence. Consequently, any advantage in disease-free survival observed at completion of therapy has been subsequently sustained for several years, suggesting this represents a real decrease rather than a postponement of treatment failure.

Age Factors↗